Knott David M Jr trimmed its stake in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 38.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,622 shares of the biopharmaceutical company’s stock after selling 8,378 shares during the period. Knott David M Jr’s holdings in Bristol Myers Squibb were worth $826,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Swiss RE Ltd. acquired a new position in shares of Bristol Myers Squibb in the fourth quarter worth about $25,000. Physician Wealth Advisors Inc. increased its position in shares of Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 202 shares in the last quarter. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb during the second quarter valued at approximately $25,000. Bayban acquired a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $31,000. Finally, EQ Wealth Advisors LLC purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at approximately $32,000. Institutional investors and hedge funds own 76.41% of the company’s stock.
Wall Street Analyst Weigh In
BMY has been the topic of several research analyst reports. UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Weiss Ratings lowered Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, July 16th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $54.00 price target on shares of Bristol Myers Squibb in a research report on Monday, July 6th. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $61.25.
Bristol Myers Squibb Trading Up 1.3%
Bristol Myers Squibb stock opened at $61.56 on Friday. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The company has a market capitalization of $125.71 billion, a price-to-earnings ratio of 17.29, a PEG ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The company’s fifty day moving average price is $57.39 and its two-hundred day moving average price is $58.00.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts forecast that Bristol Myers Squibb Company will post 6.34 earnings per share for the current fiscal year.
Bristol Myers Squibb Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 70.79%.
More Bristol Myers Squibb News
Here are the key news stories impacting Bristol Myers Squibb this week:
- Positive Sentiment: BMY was highlighted as rising while the broader market dipped, suggesting investors were rotating into the name and viewing it as relatively resilient versus the market. Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
- Positive Sentiment: Wall Street expectations point to earnings growth in next week’s report, and multiple articles framed Bristol Myers Squibb as having a strong chance to beat estimates, which can support the stock into the print. Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
- Positive Sentiment: An analyst-style momentum piece also described BMY as a top long-term momentum stock, reinforcing a constructive technical/relative-strength narrative. Why Bristol Myers Squibb (BMY) is a Top Momentum Stock for the Long-Term
- Neutral Sentiment: Bristol Myers Squibb is scheduled to report quarterly earnings next week, keeping the stock in a wait-and-see mode as investors look for confirmation of growth and guidance. Bristol Myers Squibb (BMY) to Release Quarterly Earnings on Thursday
- Neutral Sentiment: News that Alexandria Real Estate delivered a new Bristol Myers Squibb R&D hub in San Diego is operationally positive, but it is more of a long-term business development update than an immediate stock catalyst. Alexandria Real Estate Equities Delivers 427,000 RSF Bristol Myers Squibb R & D Hub
- Negative Sentiment: One MarketWatch item noted BMY underperformed peers despite daily gains, which suggests the move may be less impressive on a relative basis than it first appears. Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Featured Articles
- Five stocks we like better than Bristol Myers Squibb
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
